Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Oxaliplatin 29Fluorouracil 23Capecitabine 19pembrolizumab 17Nivolumab 16Leucovorin 16Docetaxel 10Trastuzumab 9Paclitaxel 9Cisplatin 9fludarabine 8S 1 (combination) 8Drug Therapy 8Cyclophosphamide 8Specimen Handling 7trastuzumab deruxtecan 6Bevacizumab 6Magnetic Resonance Spectroscopy 5Biopsy 5zolbetuximab 4Irinotecan 4Carboplatin 4zimberelimab 3sintilimab 3olaparib 3fludarabine phosphate 3atezolizumab 3aldesleukin 3XELOX 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × Paroxetine × 90 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡